Being overweight, obese during early adulthood associated with greater risk of pancreatic cancerJune 24, 2009Young adults who are overweight or obese have an increased risk of pancreatic cancer, and being obese at an older age is associated with a lower overall survival rate for patients with pancreatic cancer, according to a study in the June 24 issue of JAMA. Pancreatic cancer is the fourth leading cause of cancer-related death for both men and women in the United States. As the prevalence of overweight and obesity have rapidly increased during the last 2 decades, accumulating evidence has emerged that excess body weight is a risk factor for pancreatic cancer. "However, to our knowledge, no study has explicitly reported the association between excess body weight across an individual's life span and the risk of pancreatic cancer or identified at which ages the key predisposing weight change usually occurs," the authors write. Donghui Li, Ph.D., of the University of Texas M. D. Anderson Cancer Center, Houston, and colleagues conducted a study to determine the associations between body mass index (BMI) over a lifetime and pancreatic cancer risk, age at onset, and overall patient survival. The study included 841 patients with pancreatic cancer and 754 healthy individuals matched by age, race, and sex. Height and body weight histories were collected by personal interview starting at ages 14 to 19 years and over 10-year intervals progressing to the year prior to recruitment in the study. The researchers found that individuals who were overweight (a BMI of 25-29.9) from the ages of 14 to 39 years or obese (a BMI of 30 or greater) from the ages of 20 to 49 years had an associated increased risk of pancreatic cancer, independent of diabetes status. The association between average BMI (per 5-unit increase) and risk of pancreatic cancer was stronger in men than in women. The association was statistically significant for each age group from 14 to 69 years in men but only from ages 14 to 39 years in women. The estimated association of average BMI (per 5-unit increase) with cancer risk also was slightly stronger in ever smokers than in never smokers. It was estimated that 10.3 percent of never smokers and 21.3 percent of ever smokers had pancreatic cancer attributable to being overweight or obese at an early age prior to cancer diagnosis (i.e., from the ages of 14-59 years). Individuals who were overweight or obese from the ages of 20 to 49 years had an earlier onset of pancreatic cancer by 2 to 6 years (median [midpoint] age of onset was 64 years for patients with normal weight, 61 years for overweight patients, and 59 years for obese patients). Compared with those with normal body weight and after adjusting for all clinical factors, individuals who were overweight or obese from the ages of 30 to 79 years or in the year prior to recruitment had reduced overall survival of pancreatic cancer regardless of disease stage and tumor resection status. "While our observations require confirmation, they provide support for a role of excess body weight in the development and progression of pancreatic cancer," the authors conclude. JAMA and Archives Journals |
|||||||||||||||||||||
| Related Pancreatic Cancer Current Events and Pancreatic Cancer News Articles African-Americans with colorectal cancer have poorer outcomes, lower survival rates New research published in the November issue of the Journal of the American College of Surgeons shows that African-American patients with colorectal cancer are more likely to be diagnosed with advanced disease and are less likely to undergo surgical procedures compared with Caucasians, suggesting that improvements in screening and rates of operation may reduce differences in colorectal cancer outcomes for African-Americans. Discovery offers potential new pancreatic cancer treatment Tiny particles that can carry drugs and target cancer cells may offer treatment hope for those suffering with pancreatic cancer. New research to be presented in November at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Los Angeles reveals that tumor-penetrating microparticles (TPM) have been specifically designed to break through hard-to-infiltrate barriers and deliver drugs more effectively and efficiently than the standard form of chemotherapy such as those injected through a vein. Hepatitis B does not increase risk for pancreatic cancer A Henry Ford Hospital study found that hepatitis B does not increase the risk for pancreatic cancer - and that only age is a contributing factor. M. D. Anderson examines use of toad venom in cancer treatment Huachansu, a Chinese medicine that comes from the dried venom secreted by the skin glands of toads, has tolerable toxicity levels, even at doses eight times those normally administered, and may slow disease progression in some cancer patients, say researchers from The University of Texas M. D. Anderson Cancer Center. Pancreatic cancer: Researchers find drug that reverses resistance to chemotherapy For the first time researchers have shown that by inhibiting the action of an enzyme called TAK-1, it is possible to make pancreatic cancer cells sensitive to chemotherapy, opening the way for the development of a new drug to treat the disease. Endothelin-1 inhibitors in chronic pancreatitis Fibrosis is a key feature of chronic pancreatitis and pancreatic cancer. The extensive deposition of extracellular matrix proteins fosters the development of an exocrine and endocrine organ insufficiency, and accelerates progression of the tumour. Autoimmune response can induce pancreatic tumor rejection Immune responses are capable of killing tumors before they can be directed toward normal body tissue, according to new scientific findings published in Cancer Research, a journal of the American Association for Cancer Research. MicroRNAs circulating in blood show promise as biomarkers to detect pancreatic cancer A blood test for small molecules abnormally expressed in pancreatic cancer may be a promising route to early detection of the disease. Blood-flow metabolism mismatch predicts pancreatic tumor aggressiveness Researchers from Turku, Finland, have identified a blood-flow glucose consumption mismatch that predicted pancreatic tumor aggressiveness, according to results of a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research. Taking the Needle's Sting Out of Diabetes Found in 30% of all human cancer tumors, the Ras protein literally "drives cells crazy," says Prof. Yoel Kloog, the dean of the Faculty of Life Sciences at Tel Aviv University. Prof. Kloog was the first in the world to develop an effective anti-Ras drug against pancreatic cancer, currently in clinical trials. More Pancreatic Cancer Current Events and Pancreatic Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||